Pages Menu
Categories Menu

Blog

Fatty liver disease found to be very common in both younger and older people living with HIV according to cohort study in diverse population

Posted by on Sep 19, 2018 in Blog posts, Conference coverage, News | 0 comments

Fatty liver disease found to be very common in both younger and older people living with HIV according to cohort study in diverse population

  [Lance Sherriff assisted in the transcription and compilation of this article.] Fatty liver disease (hepatic steatosis) was found to be very common among people living with HIV in a cross-sectional study involving 160 people on antiretroviral treatment, according to data presented at the 9th International HIV and Aging Workshop last week in New York City. “The prevalence of hepatic steatosis was 39% for those ≥ 50 [years of age and] 49% percent for those < 50 [years of age],” said Dr. Jordan Lake of the University of Texas, Houston, though...

read more

Even newer NRTIs (anti-HIV drugs) found to cause mitochondrial damage in muscle

Posted by on Sep 18, 2018 in Blog posts, Conference coverage, News | 0 comments

Even newer NRTIs (anti-HIV drugs) found to cause mitochondrial damage in muscle

[Lance Sherriff assisted in the transcription and compilation of this article.] Mitochondria (the small organelles in cells that are critical for energy production) within the muscle fibers of antiretroviral-treated people living with HIV may be significantly damaged, according to a study presented last week in New York at the HIV and Aging Workshop by researchers from the Wellcome Centre for Microbial Research (WCMR) of Newcastle University. The study, which looked at markers of mitochondrial function using a recently developed lab...

read more

Linking people living with HIV and aging issues to appropriate care: Efforts from New York City’s Department of Health, ACT UP and NATAP

Posted by on Aug 29, 2018 in Blog posts, News | 0 comments

Linking people living with HIV and aging issues to appropriate care: Efforts from New York City’s Department of Health, ACT UP and NATAP

  Many of the aging people living with HIV suffering the most may not be able to defend themselves.  Key points: An ACT UP working group is starting to compile a list of HIV care facilities with experience treating long-term survivors and people living with HIV over the age of 50 who are experiencing aging-related comorbidities and complications — such as cardiovascular disease, hypertension, frailty, sarcopenia, and neurocognitive decline The level of detail that we currently have on most of these sites is inadequate. We would like to invite...

read more

Aging with HIV Crisis in New York City

Posted by on Aug 20, 2018 in Blog posts, News | 0 comments

Aging with HIV Crisis in New York City

Last week, two members of ACT UP NY came to the general meeting to tell us about a crisis that has befallen, by their estimation, a few dozen older HIV+ clients who were receiving care from an HIV-specialist named Olivieri based in Manhattan who was arrested a few months back. Dr. Olivieri’s practice specialized in treating older people with HIV with the co-morbidities of aging… which, in some cases, involved testosterone for those with hormonal imbalances. His arrest involved a charge that he sold a prescription to an...

read more

The high risk of frailty in middle-aged people living with HIV

Posted by on Aug 8, 2018 in Blog posts, Conference coverage, News | 0 comments

The high risk of frailty in middle-aged people living with HIV

  Frailty, the condition of depleted energy and physiological decline that is often seen in the elderly and that makes them less capable of recovering from illness, accidents and the stresses of life, has been reported to be significantly more common in people living with HIV — even in middle-aged people on antiretroviral treatment (ART) —than in people without HIV according to a growing number of studies including a recent analysis of the Multicenter AIDS Cohort Study (MACS)[1] (described in a summary on aidsmap), the Women’s Interagency HIV...

read more

AIDS 2018: Disappointing results from vedolizumab study re durable suppression off antiretroviral treatment strategy

Posted by on Jul 30, 2018 in Blog posts, News | 0 comments

AIDS 2018: Disappointing results from vedolizumab study re durable suppression off antiretroviral treatment strategy

  Last week, I retweeted a press release from the NIH about a presentation that Tony Fauci was going to make at the AIDS Conference, which featured the lead quote “Durable control of HIV infection in the absence of antiretroviral therapy is a feasible concept that deserves vigorous pursuit.” This was referring to the ‘cure’ strategy looking at whether people who have been durably suppressed on anti-HIV meds for awhile could, perhaps with the administration of other agents, develop an immune response that would keep the virus in...

read more

TB2016: The HIV and TB community’s causes are inextricably linked: Success happens together

Posted by on Jul 29, 2018 in Conference coverage, News | 0 comments

TB2016: The HIV and TB community’s causes are inextricably linked: Success happens together

TB2016 was a two-day conference dedicated exclusively to TB that immediately preceded the 21st International AIDS Conference (AIDS 2016) in Durban, South Africa. It convened TB implementers, TB scientists, infectious disease clinicians and scientists, health policy makers, and advocacy — but was held in conjunction with AIDS2016 in the hope that it would attract many of the HIV community who otherwise don’t attend TB meetings. TB2016 was a signal to both the HIV and TB communities that our causes are inextricably linked and that success...

read more

AIDS 2016: Bringing treatment programmes to scale in Africa

Posted by on Jul 29, 2018 in Conference coverage, Features and other publications, News | 0 comments

AIDS 2016: Bringing treatment programmes to scale in Africa

In the last 16 years, countries in sub-Saharan Africa have created the largest treatment programs in the world; their activists negotiated access and prices globally in its courts; and their implementers have provided the innovations in delivery to ensure coverage at community level.  This is not just reflected in treatment numbers (10.7 million) but in the innovations and the impact on mortality, life expectancy, and reduced deaths among women of childbearing age.  There were three stages in this critical innovation from Africa, which has...

read more

Treatment Science Writers site starting up again…

Posted by on Jul 29, 2018 in Blog posts, News | 0 comments

Treatment Science Writers site starting up again…

  Due to family and personal health issues, as well as our work and residences changing, this site became inactive approximately three and a half years ago. We’d like to have a more formal relaunch soon and to begin to cover stories from conferences and the medical literature again on a more regular basis. In the meantime, though, I’d like to post some updates on some of what we’ve been doing over the last few years, though the news is now a bit dated — in part, to remind myself how to use WordPress! Looking back to 2016, a couple of us...

read more

Pre-exposure prophylaxis dramatically protects against HIV infection: UK Proud study results published

Posted by on Oct 26, 2015 in News | 0 comments

Pre-exposure prophylaxis dramatically protects against HIV infection: UK Proud study results published

  Results of the United Kingdom PROUD study were published in the September 9th issue of the Lancet, following their earlier presentation at the Conference on Retroviruses and Opportunistic Infections 2015, in Seattle [1]. As reported at CROI, pre-exposure prophylaxis (PrEP) dramatically reduces the risk of HIV infection in gay men and transgender females by 86%. In addition, there was no evidence of increased high risk sex in those receiving PrEP and there was also no increase in drug resistant HIV among those receiving PrEP.   PrEP consists...

read more